CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2-metastatic breast cancer

被引:0
作者
Dent, Susan [1 ]
Guha, Avirup [2 ]
Moore, Heather [3 ]
Makari, Doris [4 ]
Mccaleb, Rachael [4 ]
Arias, Irene [4 ]
Stergiopoulos, Stella [4 ]
Li, Benjamin [4 ]
Fradley, Michael [5 ]
机构
[1] Univ Rochester, Wilmot Canc Inst, Dept Med, Rochester, NY 14627 USA
[2] Augusta Univ, Med Coll Georgia, Dept Med, Augusta, GA USA
[3] Duke Univ, Duke Canc Inst, Dept Med, Durham, NC USA
[4] Pfizer Inc, New York, NY USA
[5] Hosp Univ Penn, Thalheimer Ctr Cardiooncol, Div Cardiol, Philadelphia, PA USA
关键词
Cardiovascular comorbidities; Cyclin-dependent kinase 4/6 inhibitor; HR + /HER2-; Medical claims; Metastatic breast cancer; QTc prolongation; Retrospective; Torsades de Pointes; BREAST-CANCER; DISEASE; CLAIMS;
D O I
10.1186/s40959-025-00305-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundCardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast cancer. However, limited data are available regarding their prevalence in patients with HR + /HER2- metastatic breast cancer (mBC). We evaluated the prevalence of CV comorbidities, the use of concurrent medications with risk of QTc prolongation, and treatment patterns in patients with newly diagnosed HR + /HER2 - mBC.MethodsThis retrospective analysis utilized claims data from Merative (TM) Marketscan (R) Commercial and Medicare databases. Claims-based algorithms identified patients with newly diagnosed HR + /HER2- mBC between January 2016 and December 2022. The index date was defined as the first date of an mBC claim during this period. For each patient, data on pre-existing CV comorbidities and first-line treatments were captured for 12 months before and 6 months after the index date, respectively.ResultsA total of 6525 patients with newly diagnosed HR + /HER2 - mBC were identified. At mBC diagnosis, 61.7% of patients had >= 1 CV comorbidity. Of patients with CV comorbidities, 22.5% and 30.6% took 1 or >= 2 medications, respectively, with risk of QTc prolongation. First-line use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors increased from 22.1% of patients with CV comorbidities diagnosed in 2016-2017 to 31.5% of those diagnosed in 2018-2022.ConclusionsWe found that CV comorbidities and use of medications with risk of QTc prolongation were common in patients with newly diagnosed HR + /HER2 - mBC. These factors should inform treatment decision-making (including CDK4/6 inhibitor selection), safety discussions with patients, and CV monitoring.
引用
收藏
页数:13
相关论文
共 35 条
  • [1] [Anonymous], Merative MarketScan Research Databases 2022
  • [2] [Anonymous], NCI Comorbidity Index Overview
  • [3] Blumen H, 2016, AM HEALTH DRUG BENEF, V9, P23
  • [4] Cardiovascular Disease Mortality Among Breast Cancer Survivors
    Bradshaw, Patrick T.
    Stevens, June
    Khankari, Nikhil
    Teitelbaum, Susan L.
    Neugut, Alfred I.
    Gammon, Marilie D.
    [J]. EPIDEMIOLOGY, 2016, 27 (01) : 6 - 13
  • [5] Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update
    Burstein, Harold J.
    Somerfield, Mark R.
    Barton, Debra L.
    Dorris, Ali
    Fallowfield, Lesley J.
    Jain, Dharamvir
    Johnston, Stephen R. D.
    Korde, Larissa A.
    Litton, Jennifer K.
    Macrae, Erin R.
    Peterson, Lindsay L.
    Vikas, Praveen
    Yung, Rachel L.
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3959 - +
  • [6] Quantification of missing prescriptions in commercial claims databases: results of a cohort study
    Cepeda, Maria Soledad
    Fife, Daniel
    Denarie, Michel
    Bradford, Dan
    Roy, Stephanie
    Yuan, Yingli
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (04) : 386 - 392
  • [7] Duan Jialin, 2018, Oncotarget, V9, P25738, DOI 10.18632/oncotarget.25008
  • [8] Cardiovascular complications of ribociclib in breast cancer patients
    Fiste, Oraianthi
    Mavrothalassitis, Evangelos
    Apostolidou, Kleoniki
    Trika, Chrysanthi
    Liontos, Michalis
    Koutsoukos, Konstantinos
    Kaparelou, Maria
    Dimitrakakis, Constantine
    Gavriatopoulou, Maria
    Dimopoulos, Meletios Athanasios
    Zagouri, Flora
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [9] Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors
    Fogli, Stefano
    Del Re, Marzia
    Curigliano, Giuseppe
    van Schaik, Ron H.
    Lancellotti, Patrizio
    Danesi, Romano
    [J]. CANCER TREATMENT REVIEWS, 2019, 74 : 21 - 28
  • [10] Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer
    Franzoi, Maria Alice
    Agostinetto, Elisa
    Perachino, Marta
    Del Mastro, Lucia
    de Azambuja, Evandro
    Vaz-Luis, Ines
    Partridge, Ann H.
    Lambertini, Matteo
    [J]. LANCET ONCOLOGY, 2021, 22 (07) : E303 - E313